KIORA PHARMACEUTICALS INC — Director's Dealing 2018

Apr 27, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2018-04-25

Reporting Person: ARMISTICE CAPITAL, LLC (10% Owner)
Reporting Person: Armistice Capital Master Fund Ltd. (10% Owner)
Reporting Person: Boyd Steven (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-25	Common Stock	P	85522	$0.5408	Acquired	16332500	Direct
2018-04-25	Common Stock	P	0	—	Acquired	16332500	Indirect
2018-04-25	Common Stock	P	0	—	Acquired	16332500	Indirect
2018-04-26	Common Stock	P	80000	$0.5377	Acquired	16412500	Direct
2018-04-26	Common Stock	P	0	—	Acquired	16412500	Indirect
2018-04-26	Common Stock	P	0	—	Acquired	16412500	Indirect

Footnotes

F1: The reported securities are directly owned by Armistice Capital Master Fund, Ltd.

F2: The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: This constitutes the weighted average purchase price. The prices range from $0.5363 to $0.5459. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F4: This constitutes the weighted average purchase price. The prices range from $0.5160 to $0.5519. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.